Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ocrevus Tries Again For EU Approval Nod

Executive Summary

Just three initial marketing authorization applications are up for an opinion this week on whether they should be approved for sale across the EU. Roche’s new multiple sclerosis treatment, Ocrevus (ocrelizumab), is one, after failing to secure a positive opinion earlier. The October meeting of the panel that will decide, the European Medicines Agency’s CHMP, is under way in London.


Related Content

Roche Fails Again To Convince CHMP On Ocrevus, Only Teva Gets A Thumbs Up
CHMP Readies ‘Outstanding Issues’ Lists For Products Nearing EU Review End
Half Of All EU Fast-Track Requests Fail; AZ’s Imfinzi Among Latest
Not Just Herceptin Biosimilar: Additional 12 Drugs Set For EU Marketing Approval After CHMP Nod
‘Surprised and Disappointed’ Santhera To Fight EU’s DMD Rejection
Merck's Keytruda Claims Market Leadership In First-line Lung Cancer
Ionis Touts Inotersen's Convenience As Phase III Safety Data Disappoints
New Anti-CMV Therapies Post-Transplant: Merck & Co Leads The Pack


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts